Actelion News
Most Popular Actelion Story
Analysts give Actelion's key lung drug 63% odds of success
Swiss biotech Actelion ($ATLN) could use a win for its experimental lung drug. In need for a new product to follow its big hit Tracleer, the company's big moment for its lung disease treatment Read more...
Latest Headlines
- January 31, 2012
- December 14, 2011
- November 8, 2011
- April 13, 2011
- February 15, 2011
- February 8, 2011
- February 4, 2011
- January 28, 2011
- December 13, 2010
- November 18, 2010
- November 17, 2010
- October 21, 2010
- September 27, 2010
- July 20, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
